RE:Yesterday’s Investor Update For those who may not have time to listen to the whole webinar, following are notes I shared yesterday, which give the gist of points discussed (although formatting may be lost in the smartphone cut and paste): 1. Business overview (by Marshall): a. AI. 1) Korea strategy going along very well through a 'land and expand' approach, currently with Samsung, Lotte and 7-11 2) Canada IDEAS programme currently at Milestone 4, with the Canadian government, on $40M co-bid. TBD what portion of this will be DM's. Marshall is very optimistic given Milestone 3 was approved in only 12 hours (!!!) or so. 3) Provate sector expansion (similar to Korea approach) being worked on for Canada, the US and Europe (new) - DM now has someone covering Europe from Berlin. The provate sector strategy is ahead by many months. 4) Air Force (US) is also going along nicely AND DM is also about to present to Allied Command (NATO HQ) - date TBD. b. DM Visibiliy (IR/PR). DM currently in much better financial position, thanks to C-19 test kits sales, so in coming months intends to expand its IR/PR, in order to give DM more visibility. c. COVID-19 Testing: 1) A turnkey solution involves i. sampling by health progessional ii. provision of test kits (DM) and iii. Lab work. 2) TSX has authorized DM to sell test kits but NOT/NOT to provide a full turnkey solution (i.e. no sampling or lab work. To date DM has outsourced these, if/when requested by clients. DM is now in the process of getting into a partnership with ScreenPro, wherein ScreenPro would conduct sampling and lab work while DM would provide kits. 2. Q&A period (not comprehensive notes): ScreenPro is expected to sole source kits from DM Royalty to DM for business. TBD. In discussions PP. DM currently adequately funded. No short term PP expected BUT Marshall has not closed the door completely Profit margins on test kits. Marshall could not discuss due to competition agreements with suppliers HC/FDA test kit approvals. Both HC/FDA are bound by gag orders and cannot provide guidance to to if/when feedback may be provided regarding approval of test kits. However, both continue engaging with DM (i.e. questions etc) leading Marshall to believe things are going in the right direction Reverse split. Not expected in the near future but remains under discussion within DM. Investors will be informed futher in due course - if/as needed RPA. Marshall appears apears confident RPA provides DM an interesting new 'gamechanging' vertical/opportunity. Weaknesses: i) Financial instability. Was a concern until recently BUT now being addressed thanks to C-19 test kit income ii) IR/PR. Marshall agrees DM needs to get its name otu more. This will be addressed in the coming couple of months through a more agressinve IR/PR strategy in North America and Europe. Tech team is top notch and systematically meeting/beating timelines. Medical experts (on Board). Marshall is adamant that medical experts having joined the team where instrumental in helping DM speak effectviely and with authority with regards to C-19 testing Future C-19 sales. Marshall indicated the pandemic is not over, so believes kit sales will continue for some time. Q3 results looking really really good.
Trusted91 wrote: I missed most of the call yesterday. Does anyone have a recap of the key points or a link to the recorded video call